Health and Healthcare Systems

Indonesia is vaccinating younger people first. Here's why

A healthcare worker holds a swab sample for the coronavirus disease antigen test in Yogyakarta, Indonesia

With other countries opting to vaccine the elderly first, the world is watching this approach closely to determine its merits. Image: Hendra Nurdiyansyah/Antara Foto via REUTERS

Stanley Widianto
Politics Reporter, Reuters
Tabita Diela
Economics Reporter, Reuters
  • Indonesia is set to roll out a vaccine developed by China’s Sinovac Biotec.
  • It will be used to immunise young workers before the ageing population, with the aim of achieving herd immunity.
  • Indonesia said it does not have enough data yet of the vaccine’s efficacy on elderly people, as clinical trials underway in the country involve people aged 18-59.

As Indonesia prepares to begin mass inoculations against COVID-19, its plan to prioritise working age adults over the elderly, aiming to reach herd immunity fast and revive the economy, will be closely watched by other countries.

Several countries such as the United States and Britain that have already begun vaccinations are giving priority to elderly people who are more vulnerable to the respiratory disease.

The following are experts’ views on merits and risks of the Indonesian approach, under which working age adults will be vaccinated after frontline health workers and public servants.

Have you read?

Why 18-59 year-olds first?

Indonesia, which plans to begin mass inoculations with a vaccine developed by China’s Sinovac Biotech, says it does not have enough data yet of the vaccine’s efficacy on elderly people, as clinical trials underway in the country involves people aged 18-59.

“We’re not bucking the trend,” said Siti Nadia Tarmizi, a senior health ministry official, adding authorities would await recommendations from the country’s drug regulators to decide on vaccination plans for the elderly.

While Britain and the United States began immunizations with a shot developed by Pfizer Inc and its partner BioNTech that showed it works well in people of all ages, Indonesia has initial access only to the Sinovac vaccine.

The Southeast Asian country has a deal to receive 125.5 million doses of Sinovac’s CoronaVac shot, and a first batch of 3 million doses are already in the country.

Shipments of the Pfizer vaccine to the country are expected to begin from the third quarter, while a vaccine developed by AstraZeneca and Oxford University will start being distributed in the second quarter.

“I don’t think anybody can get too dogmatic about what is the right approach,” said Peter Collignon, professor of infectious diseases at Australian National University, adding that Indonesia’s strategy could slow the spread of the disease, although it may not affect mortality rates.

“Indonesia doing it different to the U.S. and Europe is of value, because it will tell us (whether) you’ll see a more dramatic effect in Indonesia than Europe or U.S. because of the strategy they’re doing, but I don’t think anybody knows the answer.”

Professor Dale Fisher from the Yong Loo Lin School of Medicine at the National University of Singapore said he understood the rationale of Indonesia’s approach.

“Younger working adults are generally more active, more social and travel more so this strategy should decrease community transmission faster than vaccinating older individuals,” he said.

An armed police officer stands guard next to a truck containing Sinovac's vaccine for coronavirus disease as it arrives in Palembang, Indonesia.
A truck containing the Sinovac vaccine for coronavirus. Image: Antara Foto/Nova Wahyudi/ via REUTERS

“Of course older people are more at risk of severe disease and death so vaccinating those has an alternative rationale. I see merit in both strategies.”

Will it help achieve herd immunity quickly?

By vaccinating more socially mobile and economically active groups first, Indonesian government officials hope the government can quickly reach herd immunity.

Budi Gunadi Sadikin, Indonesia’s health minister, said the country needs to vaccinate 181.5 million people, or roughly 67% of its population, to reach herd immunity, and requires almost 427 million doses of vaccines, assuming a double-dose regimen and a 15% wastage rate.

Some experts are skeptical about reaching herd immunity, as more research needs to be done to ascertain whether or not vaccinated people can transmit the virus.

“There could be the risk of people still capable of spreading the disease to the others,” said Hasbullah Thabrany, chief of the Indonesian Health Economic Association.

Officers offload a box of Sinovac's vaccine for coronavirus disease in Palembang, Indonesia.
The vaccine must be transported in chilled trucks like these, to keep the vaccine at optimum temperature. Image: Antara Foto/Nova Wahyudi/ via REUTERS

Will it help economic recovery?

Economists have argued a successful vaccination programme covering around 100 million people will help jumpstart the economy, as they are more likely to resume economic activity such as spending and production.

Faisal Rachman, an economist with Bank Mandiri, said that the 18-59 age group has consumption needs that are higher than other groups.

“They could jack up the economic recovery faster because household consumption contributes more than 50% to Indonesia’s economy,” he said, warning that rising COVID-19 cases in the country could also risk lowering people’s confidence.

The pandemic pushed Indonesia, Southeast Asia’s largest economy, into its first recession in more than two decades last year, with the government estimating a contraction of as much as 2.2%.

(This story corrects name from Rahman to Rachman in paragraph 19)

Loading...
Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Stay up to date:

Vaccination

Share:
The Big Picture
Explore and monitor how Vaccination is affecting economies, industries and global issues
World Economic Forum logo

Forum Stories newsletter

Bringing you weekly curated insights and analysis on the global issues that matter.

Subscribe today

The top global health stories from 2024

Shyam Bishen

December 17, 2024

5 ways generative AI could transform clinical trials

About us

Engage with us

  • Sign in
  • Partner with us
  • Become a member
  • Sign up for our press releases
  • Subscribe to our newsletters
  • Contact us

Quick links

Language editions

Privacy Policy & Terms of Service

Sitemap

© 2024 World Economic Forum